BioCryst Pharmaceuticals, Inc. (BCRX)
8.55
+0.26
(+3.14%)
USD |
NASDAQ |
Oct 09, 16:00
8.56
+0.01
(+0.12%)
After-Hours: 20:00
BioCryst Pharmaceuticals Cash from Operations (Quarterly) : 103.98M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 103.98M |
| March 31, 2026 | -62.14M |
| December 31, 2025 | 276.04M |
| September 30, 2025 | 41.11M |
| June 30, 2025 | 40.77M |
| March 31, 2025 | -28.03M |
| December 31, 2024 | -3.865M |
| September 30, 2024 | 7.689M |
| June 30, 2024 | -1.77M |
| March 31, 2024 | -54.07M |
| December 31, 2023 | -8.918M |
| September 30, 2023 | -19.90M |
| June 30, 2023 | -18.81M |
| March 31, 2023 | -47.51M |
| December 31, 2022 | -23.85M |
| September 30, 2022 | -32.44M |
| June 30, 2022 | -27.76M |
| March 31, 2022 | -77.80M |
| December 31, 2021 | -32.46M |
| September 30, 2021 | -23.28M |
| June 30, 2021 | -25.41M |
| March 31, 2021 | -61.01M |
| December 31, 2020 | -44.64M |
| September 30, 2020 | -38.26M |
| June 30, 2020 | -31.04M |
| Date | Value |
|---|---|
| March 31, 2020 | -23.28M |
| December 31, 2019 | -10.45M |
| September 30, 2019 | -27.64M |
| June 30, 2019 | -24.50M |
| March 31, 2019 | -27.00M |
| December 31, 2018 | -23.98M |
| September 30, 2018 | -35.03M |
| June 30, 2018 | -13.90M |
| March 31, 2018 | -19.65M |
| December 31, 2017 | -10.52M |
| September 30, 2017 | -12.43M |
| June 30, 2017 | -9.667M |
| March 31, 2017 | -8.527M |
| December 31, 2016 | -5.854M |
| September 30, 2016 | -17.56M |
| June 30, 2016 | -11.18M |
| March 31, 2016 | -18.84M |
| December 31, 2015 | -14.83M |
| September 30, 2015 | -12.66M |
| June 30, 2015 | 18.10M |
| March 31, 2015 | -3.726M |
| December 31, 2014 | -13.89M |
| September 30, 2014 | -8.60M |
| June 30, 2014 | -7.102M |
| March 31, 2014 | -8.959M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Amgen, Inc. | 4.002B |
| Halozyme Therapeutics, Inc. | 240.89M |
| Neurocrine Biosciences, Inc. | 78.00M |
| Agenus, Inc. | -31.20M |
| Anika Therapeutics, Inc. | -0.684M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -110.15M |
| Cash from Financing (Quarterly) | -10.79M |
| Free Cash Flow | 356.23M |
| Free Cash Flow Per Share (Quarterly) | 0.3913 |
| Free Cash Flow to Equity (Quarterly) | 125.21M |
| Free Cash Flow to Firm (Quarterly) | 125.19M |
| Free Cash Flow Yield | 17.61% |